Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Sea Limited (SE) Price & Performance

Heron Therapeutics IncTrade
Sea LimitedTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Sea Limited — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Sea Limited trades at $96 (market cap $56.89B). The key difference: Sea Limited is far larger — about 836.5× Heron Therapeutics Inc's market cap, and Sea Limited is more actively traded (5,359,457 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Sea Limited for 102 Days on average.

HRTXSE
Market Cap
$68.01M$56.89B
Volume
1,891,9415,359,457
Sector
HealthConsumer Cyclical
52-Week High
$1.49$188.00
52-Week Low
$0.27$78.16
Typical Hold Time
35 Days102 Days
Enterprise Value
$174.75M$51.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.

While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.

Sea Limited

Sea Limited (SE) trades at $94.66, down 1.94% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. Analyst consensus remains strongly bullish with a $153.67 price target, representing 62% upside potential from current levels.

The stock presents a compelling growth opportunity with improving profitability and strong cash flow generation, though technical weakness and insider selling create near-term headwinds. Key risks include execution challenges in e-commerce profitability and competitive pressures in Southeast Asian markets. The disconnect between strong fundamentals and bearish technicals suggests potential for recovery if earnings momentum continues.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HRTX
8% Buy92% Sell
Avg holding period · 35 Days
SE
46% Buy54% Sell
Avg holding period · 102 Days

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →

About Sea Limited

Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.

Read more on SE →